• 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br Conflicts of interest br The authors declare that there


    Conflicts of interest
    The authors declare that there are no potential conflicts of interest.
    Role of the funding source
    The funding source were not involved in this Cetuximab study.
    This study was supported by a research grant from the County of V€astmanland, Sweden (Grant number: LTV-747101).
    Table A1
    Logistic regression of risk factors for intra-abdominal infection or anastomotic leakage in patients who underwent anterior resection between 2000 and 2016.
    At risk Events Univariable
    Multivariable OR 95% CI
    Treatment group
    OR, odds ratio; CI, confidence interval; ASA, American Society of Anesthesiologists.
    Note: Only registry data. * Had not received RT for PC but have received anterior resection with pre-operative RT or CRT.
    Table A2
    Multivariable logistic regression analysis of risk factors for anastomotic leakage in patients who underwent anterior resection and had previously received radio-therapy for prostate cancer between 2000 and 2016.
    At risk Events OR 95% CI
    OR, odds ratio; CI, confidence interval; ASA, American Society of Anesthesiologists.
    Note: Registry and chart-review data.
    [1] Socialstyrelsens statistikdatabaser [Internet]. Available from: http://www. [2] Keyes M, Crook J, Morton G, Vigneault E, Usmani N, Morris WJ. Treatment options for localized prostate cancer. Can Fam Physician 2013;59(12):1269e74. [3] Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016;352. i851. [4] Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg 2011;254(6):947e50.
    [5] Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastro-enterology 2005;128(4):819e24. [6] Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008;180(5). 2005e9; discussion 9e10.
    [7] Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carci-noma patients after radiotherapy compared with surgery. Cancer 2000;88(2): 398e406.
    [9] Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18(3):336e46.
    [10] Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 2001;92(4):896e902.
    [11] Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A pro-spective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 1995;75(9):2269e75. 
    [12] Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radio-therapy for rectal cancer: reduction in local treatment failure. Eur J Canc 1994;30a(11):1602e6.
    [13] Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246(5):693e701.
    [14] Sverrisson I, Nikberg M, Chabok A, Smedh K. Low risk of intra-abdominal infections in rectal cancer patients treated with Hartmann's procedure: a report from a national registry. Int J Colorectal Dis 2018;33(3):327e32.